A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Recruiting

Phase 1

Phase 2

RSP-1502A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Sponsor:

Respirion Pharmaceuticals Pty Ltd

Code:

NCT06016088

Conditions

Cystic Fibrosis Lung

Respiratory Infections, Recurrent, Chronic

Pseudomonas Aeruginosa

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

RSP-1502

Tobramycin inhalation solution

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-10. This information was provided to ClinicalTrials.gov by Respirion Pharmaceuticals Pty Ltd on 2025-06-29.